Covid-19: US regulators allow remdesivir for hospitalised

By: |
August 29, 2020 11:55 AM

Remdesivir previously was shown to shorten treatment by about four days for hospitalized patients with severe disease, compared with those getting standard supportive care.

California-based Gilead applied to the FDA on Aug. 10 for formal approval of remdesivir.California-based Gilead applied to the FDA on Aug. 10 for formal approval of remdesivir.

U.S. regulators are now allowing use of experimental antiviral drug remdesivir for all patients hospitalized with COVID-19, drugmaker Gilead Sciences said Friday.

It said the Food and Drug Administration has expanded its emergency use authorization, which lets doctors administer the IV drug during the pandemic. Until now, that was limited to patients with severe COVID-19.

Foster City, California-based Gilead applied to the FDA on Aug. 10 for formal approval of remdesivir, to be sold under the brand name Veklury.

Gilead said in a statement that the expanded emergency use was based on results of a recent federal study of hospitalized patients with different levels of severity, plus a Gilead study published a week ago.

Gilead’s study found that among hospitalized patients with moderate COVID-19, those getting remdesivir were 65% more likely to improve after a five-day treatment course than those just getting standard care.

Remdesivir previously was shown to shorten treatment by about four days for hospitalized patients with severe disease, compared with those getting standard supportive care.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1What PM Modi said on COVID-19 vaccine at UNGA
2Ascertain reasons for spike in COVID-19 cases, reduce deaths: Tamil Nadu Chief Secretary to Collectors
3Coronavirus vaccine: Will central govt have Rs 80000 crore to vaccinate every Indian over next year, asks Serum Chief